ReCode Therapeutics
Menlo Park, US · Founded 2015 · 13 known investors
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
Founders & leadership
ReCode Therapeutics was founded in 2015 by Dr. Daniel J. Siegwart.
DD
Dr. Daniel J. Siegwart
Investors · 13
Aju IB Invesment CorporationSeoul
EcoR1 CapitalSan Francisco
Evolution VC PartnersNew York
MPM BioImpactBoston · $1M – $15M
OrbiMedNew York · $1M – $75M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pfizer Venture Investments$5M – $20M
Sanofi VenturesCambridge · $5M
Solasta VenturesBoston
Vida VenturesLos Angeles
Bioluminescence VenturesreportedSan Francisco
NVIDIAreportedSanta Clara
SEAreportedTokyo
Competitors · 2
by search overlapBioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode Therapeutics16 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Companies competing with ReCode Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does ReCode Therapeutics do?
- ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
- Who founded ReCode Therapeutics?
- ReCode Therapeutics was founded by Dr. Daniel J. Siegwart in 2015.
- Who are ReCode Therapeutics's investors?
- ReCode Therapeutics's investors include Aju IB Invesment Corporation, EcoR1 Capital, Evolution VC Partners, MPM BioImpact, OrbiMed, OUP (Osage University Partners), Pfizer Venture Investments, Sanofi Ventures and 5 more.
- Where is ReCode Therapeutics headquartered?
- ReCode Therapeutics is headquartered in Menlo Park, US.